Accelerating the development of
treatments and diagnostics for COVID-19
Project Covalence is a collaboration between TrialSpark, tech entrepreneur Sam Altman and physician-scientist Dr. Mark Fishman, to enable researchers to rapidly launch clinical trials for treatments, diagnostics, and vaccines that address COVID-19 and prevent its spread.
Communities across the globe are facing unprecedented human, economic, and social costs due to COVID-19.
As researchers across industry and academia race to identify potential new drugs, vaccines, and diagnostics to address the pandemic, the ability to test and validate them through clinical trials continues to be a major bottleneck to finding interventions that work.
Through Project Covalence, scientists, technologists, and investors are coming together to enable sponsors and investigators to rapidly stand up COVID-19 trials.
Here’s how Project Covalence can help
Funding COVID Research
Researchers around the world are racing to develop and identify potential new COVID-19 drugs, vaccines, and diagnostics.
Project Covalence offers funding to nonprofits and academic institutions to ensure researchers have the resources they need to pursue new COVID-19 treatments with the urgency that the world needs.
Launching trials, fast
Getting a clinical trial up and running is typically a long and costly process requiring the intricate coordination of people, data, and operations. During a pandemic, this is even more difficult; scientists and companies are having to reinvent the wheel for every study they run.
Project Covalence provides the blueprints for COVID-19 studies. Through access to master protocols, patient registries, and remote logistical support through TrialSpark, researchers can speed up study design, patient recruitment, and startup.
Reaching patients at home
Clinical trials often rely on traditional infrastructure like hospitals and health systems–—precisely the resources that are most tapped out during this pandemic—when some of the most important interventions, such as those that help prevent disease spread, are best run in community settings.
Project Covalence ensures that trials can still reach patients safely and smoothly during shelter-in-place orders and heightened safety precautions. Researchers have best-in-class tools at their disposal to deliver high quality remote care through Telehealth visits, at-home data collection, and medication delivery.
Powering end-to-end trials
Clinical trials have been disrupted worldwide without the resources and safeguards needed to ensure consistent, high quality data collection and trial operations remotely.
Powered by TrialSpark, Project Covalence offers the experience and technology needed to ensure end-to-end study continuity during a pandemic. Using shared staff, logistical support, and standardized infrastructure, researchers can conduct robust remote trials.
Together, we can make every shot count
The world doesn’t have time to waste. By coordinating efforts, sharing resources, and streamlining logistics, we can halt the spread of COVID-19 together.
What we can provide
Dedicated Resources & Funding
COVID-19 research funds
Strategic partnerships
Investor networks
Streamlined Trial Operations
Clinical operations + logistics
Direct-to-patient IP distribution
At-home testing + specimen collection
Innovative Study Design & Startup
Protocol development
IRB submission
Budget development
Robust Technology Infrastructure
GCP-compliant data capture platform
Patient self-reported outcomes
Telehealth and virtual study visits
Patient Recruitment & Engagement
Recruitment strategy development
Curated patient registries
Digital patient recruitment
Data Analysis & Closeout
Real-time reporting + analytics
Data management
Biostatistics + analysis
